Denali Therapeutics, Inc. announced that its strategic partner Takeda Pharmaceutical Company Limited has exercised an option to co-develop and co-commercialize DNL593, an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.
[Denali Therapeutics, Inc.]
7992332
{7992332:CCCCCCCC}
apa
50
1
169048
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
